Verastem Inc. (VSTM)
Symbol Info
Listed Symbol VSTM
Name Verastem Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $26,718,000
Latest Fiscal EPS $-1.38
Price Info
21 Day Moving Average $1.2388
21 Day EMA $1.208690
50 Day Moving Average $1.2794
50 Day EMA $1.292830
200 Day EMA $2.271760
200 Day Moving Average 2.144900
52 Week High $6.33
52 Week Low $1.08
52 Week Change $-82.504000
Alpha -0.025004
Beta 2.9350
Standard Deviation 0.245108
R2 0.169269
Periods 60
Share Information
10 Day Average Volume 944,291
20 Day Average Volume 755,660
30 Day Average Volume 779,027
50 Day Average Volume 815,544
Outstanding Shares 74,140,687
Float Shares 72,107,921
Percent Float 97.26%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 236
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 6,381,172
Institute Holdings Percent 51.300000
Institute Sold Previous 3 Months 21,586,313
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 13
Insider Holdings Percent 2.70%
Insider Sold Previous 3 Months -
Insiders Shares Owned 2,032,766
Price Change
7 Day Price Change $-0.1
7 Day Percent Change -8.40%
21 Day Price Change $-0.24
21 Day Percent Change -18.05%
30 Day Price Change $-0.26
30 Day Percent Change -19.26%
Month To Date Price Change $-0.12
Month To Date Percent -9.92%
90 Day Price Change $-0.46
90 Day Percent Change -29.68%
Quarter To Date $-0.12
Quarter To Date Percent -9.92%
180 Day Price Change $-1.63
180 Day Percent Change -59.93%
200 Day Price Change $-2.24
200 Day Percent Change -67.27%
Year To Date $-2.27
Year To Date Percent -67.56%
Profile
Description Verastem Oncology is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The Company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.
Details
Issue Type CS
Market Cap $80,813,349
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 74,140,687
CEO Brian M. Stuglik
Employees 169
Last Audit UQ
Classification
CIK 0001526119
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 117 Kendrick Street
Suite 500
Needham, MA 2494
Website https://www.verastem.com
Facisimile
Telephone +1 781 292-4200
Email rgagnon@verastem.com
Key Ratios
Profitability
EBIT Margin -457.1
EBITDA Margin -448.9
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin 93.10
Profit Margin TOT -
Income Statements
Revenue $6,017,000
Revenue Per Share $0.0812
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $40,281,231
Price To Sales 13.430839
Price To Free Cash -0.7
PE High Last 5 Years -
Price To Book 1.7
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 2.9
Financial Strength
Total Debt To Equity 2.8
Int Coverage -6.6
Current Ratio 6.2
Leverage Ratio 3.6
Quick Ratio 6.0
Long Term Debt To Capital 0.74
Assets
Receivables Turnover 1.0
Invoice Turnover 7.00
Assets Turnover -
Management Effectiveness
Return Assets -57.89
Return On Equity -128.64
Return On Capital -60.91
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
VSTM
Verastem
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.